Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 923

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1A
Chunk 923
---
6 million have been recognized
in relation to this share re-price.

    F-22

BEYOND AIR, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 STOCKHOLDERS’ EQUITY (continued)

The Company’s 2021 Beyond Cancer Ltd. Equity
Incentive Plan (the “2021 BC Plan”) allows for awards to officers, directors, employees, and consultants of stock options,
restricted stock units and restricted shares of Beyond Cancer Ltd.’s common stock. The vesting terms of the options issued under
the 2021 BC Plan are generally four years and they expire ten years from the grant date. On November 3, 2022, the Company’s Board
of Directors approved an amendment to reserve for issuance an additional 2,000,000 shares of common stock. The 2021 BC Plan has 4,000,000
shares authorized for issuance. As of March 31, 2025, 1,183,750 shares were available under the 2021 BC Plan.

A summary of the change in stock options for Beyond
Cancer for the years ended March 31, 2025 and March 31, 2024 is as follows:

 SCHEDULE
OF OPTION ACTIVITY FOR BEYOND
CANCER

    Number Of Options  
    Weighted Average Exercise Price–- Options  
    Weighted Average Remaining Contractual Life-  Options  
    Aggregate Intrinsic Value (thousands) 

    Options outstanding as of March 31, 2023 
     3,817,000  
    $2.88  
     9.2  
    $23,486 
  
    Granted 
     155,000  
     5.50  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     (153,000) 
     5.50  
     -  
     - 
  
    Options outstanding as of March 31, 2024 
     3,819,000  
    $5.50  
     8.3  
    $- 
  
    Granted 
     -  
     -  
     -  
     - 
  
    Exerc